Press Releases

Data from Intensity Therapeutics’ Phase 1/2 Study of INT230-6 Highlight Prolonged Disease Control, Abscopal Effects and Immune Response Activity in Patients with Advanced Solid Tumors

Nov 15 2019

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of solid cancers, today announced new preliminary data from the ongoing Phase 1/2 clinical study of INT230-6, the Company’s lead product candidate. These data will be presented on Saturday, November 9, in an oral podium… Read more »

Intensity Therapeutics Treats First Patient with Combination of INT230-6 and Merck’s Keytruda®

Oct 15 2019

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune system recognition of solid cancers, today announced that the first patient has been dosed with a combination of INT230-6, the Company’s lead investigational product, and Keytruda® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy. The combination is being… Read more »

Intensity Therapeutics’ Intratumoral INT230-6 Tumor Regression and Immune Response Activity Data Selected for Oral Presentation at SITC 2019 Conference

Oct 15 2019

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of solid cancers, today announced that data from the ongoing clinical trial of its lead product candidate INT230-6 was selected for a podium presentation at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting,… Read more »

View All Press Releases

Publications/Papers/Posters

OncoImmunology July 16, 2019 Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory

Article published on-line July 16, 2019 in the journal OncoImmunology.  https://doi.org/10.1080/2162402X.2019.1625687 Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. ABSTRACT The benefits of anti-cancer agents extend beyond direct tumor killing. One aspect of cell death is the potential to release antigens that initiate adaptive immune responses. Here, a… Read more »

ASCO 2019 Poster Presentation – Abstract 2602

Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation  

SITC 2018 Poster Presentation P622

Phase 1/2 Evaluation of Intratumoral INT230-6 for the Treatment of Solid Tumors

View All Publications/Papers/Posters